Coherus Oncology, Inc. (CHRS) trades at a trailing P/E of 1.2, forward P/E of 6.2. Trailing earnings yield is 85.38%, forward earnings yield 16.13%. Graham Number is $3.99.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -9.3 | 0.19 | 60.96 | 6.21 | - |
| 2017 | -2.0 | -0.04 | 15.31 | 300.50 | - |
| 2018 | -2.8 | 0.10 | -15.25 | 378.12 | - |
| 2019 | 14.0 | -0.10 | 11.92 | 3.52 | - |
| 2020 | 9.4 | 0.22 | 4.42 | 2.61 | - |
| 2021 | -4.2 | 0.01 | 12.32 | 3.69 | - |
| 2022 | -2.1 | 1.61 | -4.47 | 2.91 | - |
| 2023 | -1.3 | 0.04 | -1.62 | 1.22 | - |
| 2024 | 5.5 | -0.05 | -1.20 | 0.59 | - |
| 2025 | -1.0 | 0.00 | 2.80 | 4.05 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-3.04 | $190.11M | $-127.34M | -67% |
| 2017 | $-4.48 | $1.56M | $-238.17M | -15306.6% |
| 2018 | $-3.22 | $1.56M | $-209.34M | -13453.7% |
| 2019 | $1.23 | $356.07M | $89.83M | 25.2% |
| 2020 | $1.62 | $475.82M | $132.24M | 27.8% |
| 2021 | $-4.06 | $326.55M | $-306.32M | -93.8% |
| 2022 | $-4.21 | $211.04M | $-326.63M | -154.8% |
| 2023 | $-2.53 | $257.24M | $-237.89M | -92.5% |
| 2024 | $0.25 | $266.96M | $28.51M | 10.7% |
| 2025 | $-1.45 | $42.17M | $-170.29M | -403.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.96 | $-1.40 – $-0.71 | $84.37M | $58.45M – $132.95M | 2 |
| 2027 | $-0.92 | $-1.33 – $-0.67 | $112.44M | $89.88M – $124.32M | 2 |
| 2028 | $-0.66 | $-0.87 – $-0.35 | $187.21M | $187.21M – $187.21M | 4 |
| 2029 | $-0.30 | $-0.43 – $-0.22 | $260.52M | $206.69M – $350.79M | 2 |
| 2030 | $0.30 | $0.22 – $0.44 | $356.78M | $283.05M – $480.41M | 2 |
